THERAPEUTIC AGENT FOR RHINITIS
The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects. Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.
1 .- 23 . (canceled)
24 . A therapeutic preparation for rhinitis comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.
25 . The therapeutic preparation for rhinitis according to claim 24 , wherein the C-type natriuretic peptide (CNP) is CNP-22, CNP-53, or a CNP derivative in which any amino acid in the amino acid sequence(s) of CNP-22 or CNP-53 is/are deleted, substituted or added, and which has CNP activity.
26 . The therapeutic preparation for rhinitis according to claim 24 , wherein the B-type natriuretic peptide (BNP) is BNP-26, BNP-32, BNP-45, or a BNP derivative in which any amino acid(s) in the amino acid sequence of BNP-26, BNP-32, or BNP-45 is/are deleted, substituted or added, and which has BNP activity.
27 . The therapeutic preparation for rhinitis according to claim 24 , wherein the C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) is a chimeric peptide of CNP and BNP forming a ring structure by an intramolecular disulfide bond,
in which the CNP is a peptide selected from the group consisting of CNP-22, CNP-53, a peptide comprising any amino acid sequence of 5 or more consecutive amino acids in the amino acid sequence of CNP-22 having deletion(s), substitution(s), or addition(s) of any 1-5 amino acid(s), or a peptide comprising any amino acid sequence of 5 or more consecutive amino acids in the amino acid sequence of CNP-53 having deletion(s), substitution(s), or addition(s) of any 1-5 amino acid(s),
and in which the BNP is a peptide selected from the group consisting of BNP-26, BNP-32, BNP-45, a peptide comprising any amino acid sequence of 5 or more consecutive amino acids in the amino acid sequence of BNP-26 having deletion(s), substitution(s), or addition(s) of any 1-5 amino acid(s), a peptide comprising any amino acid sequence of 5 or more consecutive amino acids in the amino acid sequence of BNP-32 having deletion(s), substitution(s), or addition(s) of any 1-5 amino acid(s), or a peptide comprising any amino acid sequence of 5 or more consecutive amino acids in the amino acid sequence of BNP-45 having deletion(s), substitution(s), or addition(s) of any 1-5 amino acid(s),
and wherein the chimeric peptide has CNP activity or BNP activities; or a derivative of the chimeric peptide.
28 . The therapeutic preparation for rhinitis according to claim 24 , wherein the concentration of the C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) is 20-200 μg/g.
29 . The therapeutic preparation for rhinitis according to claim 24 , wherein the concentration of the C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) is 50-200 μg/g.
30 . The therapeutic preparation for rhinitis according to claim 24 , wherein the concentration of the C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) is 50-100 μg/g.
31 . The therapeutic preparation for rhinitis according to claim 24 , wherein the rhinitis is infectious rhinitis, hypersensitive non-infectious rhinitis, irritant rhinitis, atrophic rhinitis, or specific granulomatous rhinitis.
32 . The therapeutic preparation for rhinitis according to claim 31 , wherein the infectious rhinitis is acute rhinitis or chronic rhinitis.
33 . The therapeutic preparation for rhinitis according to claim 31 , wherein the hypersensitive non-infectious rhinitis is combined-type rhinitis (hypersensitive nose), rhinorrhea-type rhinitis, congestive-type rhinitis, or dry-type rhinitis.
34 . The therapeutic preparation for rhinitis according to claim 33 , wherein the combined-type rhinitis (hypersensitive nose) is allergic rhinitis or non-allergic rhinitis.
35 . The therapeutic preparation for rhinitis according to claim 34 , wherein the allergic rhinitis is allergic rhinitis against at least one allergen selected from the group consisting of house dust, mite, cedar, orchard grass, ragweed, and cat hair.
36 . The therapeutic preparation for rhinitis according to claim 31 , wherein the irritant rhinitis is physical irritant-induced rhinitis, chemical irritant-induced rhinitis or radiation-induced rhinitis.
37 . The therapeutic preparation for rhinitis according to claim 24 , wherein the rhinitis is mixed-type rhinitis, sneezing/rhinorrhea-type rhinitis, or nasal-occlusion-type rhinitis.
38 . The therapeutic preparation for rhinitis according to claim 24 , wherein the dosage form is a nasal drop preparation selected from an ointment preparation, a gel preparation, a cream preparation, a lotion preparation, a liquid preparation, a powder preparation or a spray preparation.
39 . The therapeutic preparation for rhinitis according to claim 24 , wherein the rhinitis is rhinitis in a subject suffering from atopic dermatitis or a subject having a difficulty in withdrawal from steroids.
40 . The therapeutic preparation for rhinitis according to claim 28 , wherein the rhinitis is allergic rhinitis or non-allergic rhinitis.
41 . The therapeutic preparation for rhinitis according to claim 28 , wherein the dosage form is a nasal drop preparation selected from an ointment preparation, a gel preparation, a cream preparation, a lotion preparation, a liquid preparation, a powder preparation or a spray preparation.
42 . The therapeutic preparation for rhinitis according to claim 34 , wherein the dosage form is a nasal drop preparation selected from an ointment preparation, a gel preparation, a cream preparation, a lotion preparation, a liquid preparation, a powder preparation or a spray preparation.
43 . The therapeutic preparation for rhinitis according to claim 40 , wherein the dosage form is a nasal drop preparation selected from an ointment preparation, a gel preparation, a cream preparation, a lotion preparation, a liquid preparation, a powder preparation or a spray preparation.
44 . The therapeutic preparation for rhinitis according to claim 24 , wherein the rhinitis is rhinitis with treatment resistance to steroids or antihistamine drugs.
45 . The therapeutic preparation for rhinitis according to claim 28 , wherein the rhinitis is rhinitis with treatment resistance to steroids or antihistamine drugs.
46 . The therapeutic preparation for rhinitis according to claim 34 , wherein the rhinitis is rhinitis with treatment resistance to steroids or antihistamine drugs.
47 . The therapeutic preparation for rhinitis according to claim 38 , wherein the rhinitis is rhinitis with treatment resistance to steroids or antihistamine drugs.
48 . The therapeutic preparation for rhinitis according to claim 40 , wherein the rhinitis is rhinitis with treatment resistance to steroids or antihistamine drugs.